DissoCubes

DissoCubes™ are crystalline nanoparticles of active substance obtained by a liquid state high energy process using a high pressure piston gap homogenizer to reduce the drug particle size in the presence of surface modifiers that associate at the freshly generated drug interface. A particle size reduction from approximately 50µm to about 0.5µm is achieved resulting in a very homogenous and stable formulation. The nanosuspensions could be formulated into various dosages forms.

DissoCubes™ technology is a technology of choice for molecules with oral bioavailability issues and/or requiring rapid onset of absorption.

SkyePharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 105 Piccadilly, London, W1J 7NJ, United Kingdom

For enquiries, please
contact us.

Home
Technology
Inhalation Technology
Oral Technology